Santini V - Search Results

1

Azacitidine in lower-risk myelodysplastic syndromes.

Santini V. Santini V. Leuk Res. 2009 Dec;33 Suppl 2:S22-6. doi: 10.1016/S0145-2126(09)70230-9. Leuk Res. 2009. PMID: 20004794

2

The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes.

Rossi Ferrini P, Santini V, Ciolli S, Grossi A, Leoni F, Rafanelli D, Vannucchi AM. Rossi Ferrini P, et al. Among authors: santini v. Hematol Oncol. 1993;11 Suppl 1:32-5. Hematol Oncol. 1993. PMID: 7683622 Review. No abstract available.

3

Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.

Santini V, D'Ippolito G, Bernabei PA, Zoccolante A, Ermini A, Rossi-Ferrini P. Santini V, et al. Leuk Res. 1996 Jan;20(1):37-45. doi: 10.1016/0145-2126(95)00106-9. Leuk Res. 1996. PMID: 8632676

4

Differentiation therapy of myelodysplastic syndromes: fact or fiction?

Santini V, Ferrini PR. Santini V, et al. Br J Haematol. 1998 Sep;102(5):1124-38. doi: 10.1046/j.1365-2141.1998.00881.x. Br J Haematol. 1998. PMID: 9753034 Free article. Review. No abstract available.

5

Amifostine in the treatment of low-risk myelodysplastic syndromes.

Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, Pagliai G, Ciolli S, Rossi Ferrini P. Grossi A, et al. Among authors: santini v. Haematologica. 2000 Apr;85(4):367-71. Haematologica. 2000. PMID: 10756361 Clinical Trial.

6

Treatment options in myelodysplastic syndromes: a new frontier.

Santini V, Gozzini A, Bosi A. Santini V, et al. J Chemother. 2008 Jun;20(3):291-6. doi: 10.1179/joc.2008.20.3.291. J Chemother. 2008. PMID: 18606581 Review.

7

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Fenaux P, et al. Among authors: santini v. Lancet Oncol. 2009 Mar;10(3):223-32. doi: 10.1016/S1470-2045(09)70003-8. Epub 2009 Feb 21. Lancet Oncol. 2009. PMID: 19230772 Free PMC article. Clinical Trial.

8

Is survival enough for myelodysplastic syndromes?

Santini V. Santini V. Leuk Res. 2009 Aug;33(8):1017-8. doi: 10.1016/j.leukres.2009.02.001. Epub 2009 Mar 5. Leuk Res. 2009. PMID: 19268362 No abstract available.

9

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, Zini G, Petti MC, Martinelli G, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, Amadori S, Leone G. Voso MT, et al. Among authors: santini v. Clin Cancer Res. 2009 Aug 1;15(15):5002-7. doi: 10.1158/1078-0432.CCR-09-0494. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638460 Free article. Clinical Trial.

10

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.

Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di Maio M, Finelli C, Locatelli F, Marchetti M, Morra E, Musto P, Visani G, Tura S; Italian Society of Hematology. Santini V, et al. Leuk Res. 2010 Dec;34(12):1576-88. doi: 10.1016/j.leukres.2010.01.018. Epub 2010 Feb 11. Leuk Res. 2010. PMID: 20149927

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters